BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen ZL, Liang YJ, Xing H, Yang T. Is delayed surgery justified for patients with hepatocellular carcinoma? Surgery 2020;167:1023. [PMID: 31898952 DOI: 10.1016/j.surg.2019.11.020] [Reference Citation Analysis]
2 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
3 Taylor EJ, Jones RL, Guthrie JA, Rowe IA. Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology 2017;66:1546-55. [DOI: 10.1002/hep.29315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
4 Doyle A, Sherman M. Liver Biopsy for Hepatocellular Carcinoma (HCC): Should this be a Routine? Curr Hepatology Rep 2017;16:46-50. [DOI: 10.1007/s11901-017-0333-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
5 Sherman M. Surveillance of Hepatocellular Carcinoma: We Must Do Better. The American Journal of Medicine 2008;121:89-90. [DOI: 10.1016/j.amjmed.2007.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant 2015;29:52-9. [PMID: 25366656 DOI: 10.1111/ctr.12480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
8 Rengo M, Bellini D, De Cecco CN, Osimani M, Vecchietti F, Caruso D, Maceroni MM, Lucchesi P, Iafrate F, Palombo E, Paolantonio P, Ferrari R, Laghi A. The optimal contrast media policy in CT of the liver. Part II: Clinical protocols. Acta Radiol 2011;52:473-80. [PMID: 21498280 DOI: 10.1258/ar.2011.100500] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
9 Terzi E, Salvatore V, Negrini G, Piscaglia R. Ongoing challenges in the diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2015;Nov 24; Epub ahead of print. [PMID: 26603785 DOI: 10.1586/17474124.2016.1124758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
10 Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol. 2015;24:335-345. [PMID: 25560752 DOI: 10.1016/j.intimp.2014.12.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
11 Quan B, Yan W, Lau WY, Wu M, Yang T. Impact of delayed time from diagnosis to treatment on the stage of hepatocellular carcinoma. Hepatobiliary & Pancreatic Diseases International 2019;18:100. [DOI: 10.1016/j.hbpd.2018.09.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Sherman M. Limitations of screening for hepatocellular carcinoma. Hepat Oncol 2014;1:161-3. [PMID: 30190948 DOI: 10.2217/hep.13.22] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 2010;16:1186-94. [PMID: 20879017 DOI: 10.1002/lt.22129] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
14 Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, Jiang J, Huang X, Tong H, Tian Y. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7:1670-1679. [PMID: 29573235 DOI: 10.1002/cam4.1390] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
15 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
17 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
19 Carter HE, Jeffrey GP, Ramm GA, Gordon LG. Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma. Value Health 2021;24:1454-62. [PMID: 34593168 DOI: 10.1016/j.jval.2021.04.1286] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
21 Xie L, Yin J, Xia R, Zhuang G. Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology 2018;68:1476-86. [PMID: 29633304 DOI: 10.1002/hep.29922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]